The research group led by Assistant Professor Kunihiko Morihiro and Professor Akimitsu Okamoto from the Graduate School of Engineering, were inspired to create a new anticancer drug using artificial DNA.
"We thought that if we can create new drugs that work by a different mechanism of action from that of conventional drugs, they may be effective against cancers that have been untreatable up to now," said Okamoto.
This procedure was successful in lab tests against cells generated from human cervical cancer, human breast cancer, and mouse malignant melanoma.
The group was given a pair of hairpin-shaped, cancer-curing DNA molecules using chemical synthesis. The DNA pairs linked to microRNA (miRNA) molecules that are overproduced in some tumours when they were injected into cancer cells. They unwound and combined after they were bound to the miRNA to produce longer DNA chains, which stimulated an immunological response.
Apart from eliminating the cancer cells, this reaction also stopped the spread of malignant tissue. It is envisaged that this approach, which differs from traditional anticancer drug therapies, would usher in a new era of drug discovery.
Cancer is a sadly familiar global health concern and current methods of treatment have their limitations. However, drugs based on nucleic acids -- namely DNA and RNA, the vital information-carrying molecules -- can control the biological functions of cells, and are expected to transform the future of medicine and provide a significant boost towards efforts to overcome cancer and other hard-to-treat illnesses, caused by viruses and genetic diseases.
Nucleic acid drug use for cancer treatment has been challenging because it is difficult to make the nucleic acids distinguish between cancer cells and other healthy cells. This means there is a risk of adversely affecting the patient's immune system if healthy cells are inadvertently attacked. However, for the first time, the team was able to develop a hairpin-shaped DNA strand that can activate a natural immune response to target and kill specific cancerous cells.
Cancer cells can overexpress, or make too many copies of, certain DNA or RNA molecules, causing them to not function normally. The team created artificial oncolytic (cancer-killing) hairpin DNA pairs called oHPs. These oHPs were triggered to form longer DNA strands when they encountered a short (micro) RNA called miR-21, which is overexpressed in some cancers.
Typically, oHPs don't form longer strands due to their curved hairpin shape. However, when the artificial oHPs enter a cell and encounter the target microRNA, they open up to combine with it and form a longer strand. This then causes the immune system to recognize the presence of the overexpressed miR-21 as dangerous and activate an innate immune response, which ultimately leads to the death of the cancer cells.
The tests were effective against overexpressed miR-21 found in human cervical cancer-derived cells, human triple-negative breast cancer-derived cells, and mouse malignant melanoma-derived cells.
"The formation of long DNA strands due to the interaction between short DNA oHPs and overexpressed miR-21, found by this research group, is the first example of its use as a selective immune amplification response which can target tumor regression, providing a new class of nucleic acid drug candidates with a mechanism that is completely different from known nucleic acid drugs," said Okamoto.
"The results of this study are good news for doctors, drug discovery researchers and cancer patients, as we believe it will give them new options for drug development and medication policies. Next, we will aim for drug discovery based on the results of this research, and examine in detail the drug efficacy, toxicity and potential administration methods."
This research still has many steps to go before a treatment can be made available, but the team is confident in the benefits of nucleic acids for new drug discovery.
(With inputs from ANI)